Later studies showed RABL6A is essential for the growth and survival of various tumor types, controls central cancer pathways (RB1, p53, PP2A, AKT, mTOR, ERK), and is a biomarker of poor survival in several cancers including breast and pancreatic adenocarcinomas [7,8,9,10,11,12,13,14,15]. Here, AKT1 is linked to cancer.